4.4 Review

The current landscape of early drug development for patients with sarcoma in the immunotherapy era

期刊

FUTURE ONCOLOGY
卷 14, 期 12, 页码 1197-1211

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/fon-2017-0565

关键词

immunotherapy; PD-1; PD-L1; sarcoma; treatment; trials

类别

资金

  1. Instituto Salud Carlos III [JR14/00006]

向作者/读者索取更多资源

Immunotherapy has changed the treatment paradigm of melanoma and other malignancies. Recently, trials of checkpoint inhibition in sarcomas have been far from outstanding, although specific sarcoma subtypes appear to benefit from these novel therapies. The next steps involve combining immune checkpoint inhibition with classic cancer therapies in order to increase immunogenicity and also potentially complex immunotherapy techniques such as adoptive cell therapy. Currently, numerous clinical trials are exploring different immunotherapies in the sarcomas. Herein, we describe some of the preclinical and clinical data that have laid the groundwork for the use of immunotherapies in sarcomas, as well as the current and future studies that could make immunotherapy a therapeutic option for patients with sarcoma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据